Patent · US Active

Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazole

US11130777B2 · kind B2 · utility

4Cited by
6References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 22, 2019
Grant dateSep 28, 2021
Priority date
Expiry dateMar 22, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.